 "Wockhardt plans tie-ups for next-gen Covid-19 vax, aims to make 2 bn doses")
Mumbai-headquartered drug maker Wockhardt, which has injectables plants in India and the UK, is crafting a three-pronged strategy for developing a Covid-19 vaccine portfolio.
While the transfer of technology for one foreign Covid-19 vaccine is underway, the company is also in talks with two more overseas manufacturers for collaboration on the already-approved vaccines. Besides, it is also in discussions with research-driven companies that are in clinical stages of developing next-generation Covid vaccines. These could be oral or nasal.
The firm did not divulge the names, but said an announcement was likely in the next two to three weeks with regard to a
